Der Schweizer Pharmariese Novartis hat einer kürzlich publizierten Pressemitteilung die Zusage vor Forschung an seltenen und nicht unbedingt Umsatz-generierenden Pharmazeutika bestätigt.
Neben der erfolgreichen Entwicklung von Glivec (Imatinib), welches einen Umbruch am Arzneimittelmarkt darstellte, ist Novartis weiterhin an der Entwicklung von Medikamenten interessiert dir nur für kleine Patientenkollektive von Bedeutung ist. Dies ist inbesondere wichtig, da Pharmamultis in der Regel auf “sichere” und “große” Krankheitsbilder wie Herz-Kreislauf und Krebs setzten und dahingehend die Entwicklung voranzutreiben.
Die Pressemitteilung von Novartis beinhaltet eine Liste von sich in Entwicklung befindlichen Wirkstoffen:
Tasigna – ENESTnd 24-month update comparing Tasigna to Glivec in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (ASH Abstract #207; Dec. 6; 7:30 AM EST)[3].
Afinitor– Two studies showing activity of everolimus in mantle cell lymphoma (ASH Abstract #2803; Dec. 5; 6:00-8:00 PM EST)[4];
(ASH Abstract #3963; Dec. 6; 6:00-8:00 PM EST)[5].
Exjade – EPIC sub-studies presenting three-year, end-of-study data on cardiac iron removal (ASH Abstract #4276; Dec. 6; 6:00-8:00 PM EST)[6] and post-hoc analysis from a large study reporting hematologic response in a cohort of MDS patients (ASH Abstract #2912; Dec. 5; 6:00-8:00 PM EST)[7]; the first study (109E) to report on long-term safety and efficacy in sickle-cell disease patients up to five years (ASH Abstract #845; Dec. 6; 7:15 PM EST)[8]; and the first large study (107E/108E) to assess effect of iron chelation therapy on liver pathology in large cohort of beta-thalassemia patients (ASH Abstract #4274; Dec. 6; 6:00-8:00 PM EST)[9].
Zometa – Phase III data evaluating Zometa in the treatment of patients with newly diagnosed multiple myeloma (ASH Abstract #311; Dec. 6; 8:00 AM EST)[10].
LBH589 (panobinostat) – Pivotal Phase II data for LBH589 in the treatment of Hodgkin lymphoma patients who relapse or are refractory after autologous stem cell transplant (ASH Abstract #419; Dec. 6; 11:30 AM EST) [11].
INC424[i] – Phase II data showing response rates to INC424 in patients with polycythemia vera (ASH Abstract #313; Dec. 6; 7:00 AM EST)[12]; Phase II data of INC424 in patients with refractory leukemias including post-myeloproliferative disorder and acute myeloid leukemia (ASH Abstract #509; Dec. 6; 3:45 PM EST)[13].
PKC412 (midostaurin) – Phase II data evaluating midostaurin in the treatment of aggressive systemic mastocytosis (ASH Abstract #316; Dec. 6; 7:45 AM EST)[14].
HCD122 (lucatumumab) – Clinical activity evaluated in patients with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a Phase Ia/II trial (ASH Abstract #284; Dec. 6; 7:15 AM EST) [15].
Weiterführende Informationen finden Sie hier.
